Fesoterodine

Generic Name: Fesoterodine

Brand Names: Toviaz

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₇NO_₃

CAS Number: 286930-02-7

Unique Ingredient Identifier: 621G617227

Background: Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

Indication: 适用于治疗急迫性尿失禁和膀胱过度活动综合征患者的尿频、尿急、尿失禁或所有这些症状组合。

Associated Conditions: Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)

Clinical Trials

Phase 1, Single Dose, Crossover Study to Determine Bioequivalence and to Investigate Food Effect

Phase 1

Completed

Conditions: Therapeutic Equivalency
Food

Interventions: Drug: Fesoterodine

First Posted Date: 2008-12-11

Last Posted Date: 2010-03-24

Lead Sponsor: Pfizer

Target Recruit Count: 108

Registration Number: NCT00807118

Locations: 🇯🇵
Pfizer Investigational Site, Shinjuku-ku, Tokyo, Japan

UK Study Assessing Flexible Dose Fesoterodine in Adults

Phase 4

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: Fesoterodine

First Posted Date: 2008-12-10

Last Posted Date: 2011-01-26

Lead Sponsor: Pfizer

Target Recruit Count: 331

Registration Number: NCT00806494

Locations: 🇬🇧
Pfizer Investigational Site, Swindon, United Kingdom

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.

Phase 4

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: Placebo
Drug: Fesoterodine fumarate

First Posted Date: 2008-11-26

Last Posted Date: 2011-12-14

Lead Sponsor: Pfizer

Target Recruit Count: 794

Registration Number: NCT00798434

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

Phase1, Single Dose, Crossover Study to Determine Bioequivalence

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Fesoterodine

First Posted Date: 2008-11-06

Last Posted Date: 2010-09-09

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT00786240

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients

Early Phase 1

Withdrawn

Conditions: Urinary Incontinence
Bladder Dysfunction

First Posted Date: 2008-07-14

Last Posted Date: 2018-09-11

Lead Sponsor: Saint Thomas Health

Registration Number: NCT00713921

Locations: 🇺🇸
Vanderbilt Univiersity, Nashville, Tennessee, United States

Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy

Completed

Conditions: Overactive Bladder
Urinary Incontinence

Interventions: Drug: fesoterodine

First Posted Date: 2008-06-05

Last Posted Date: 2018-11-02

Lead Sponsor: Pfizer

Target Recruit Count: 823

Registration Number: NCT00691093

Locations: 🇸🇰
Pfizer Investigational Site, Zvolen, Slovakia

Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: fesoterodine fumarate

First Posted Date: 2008-04-15

Last Posted Date: 2010-10-13

Lead Sponsor: Pfizer

Target Recruit Count: 153

Registration Number: NCT00658684

Locations: 🇯🇵
Pfizer Investigational Site, Shibuya-ku, Tokyo, Japan

Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.

Phase 3

Completed

Conditions: Overactive Bladder

Interventions: Drug: Tolterodine ER
Drug: Placebo
Drug: Fesoterodine

First Posted Date: 2008-02-08

Last Posted Date: 2011-02-02

Lead Sponsor: Pfizer

Target Recruit Count: 2417

Registration Number: NCT00611026

Locations: 🇺🇦
Pfizer Investigational Site, Zaporizhzhia, Ukraine

An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia

Phase 4

Completed

Conditions: Bladder Outlet Obstruction

Interventions: Drug: Toviaz (Fesoterodine)

First Posted Date: 2008-01-31

Last Posted Date: 2018-04-10

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 17

Registration Number: NCT00605319

Locations: 🇺🇸
New York Hospital, Cornell University, New York, New York, United States

Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

Phase 2

Completed

Conditions: Overactive Bladder

Interventions: Drug: fesoterodine fumarate
Drug: Placebo

First Posted Date: 2007-11-21

Last Posted Date: 2011-07-14

Lead Sponsor: Pfizer

Target Recruit Count: 951

Registration Number: NCT00561951

Locations: 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy